BioGend Therapeutics Co., Ltd.

6733

TW0006733009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
37 ^TWD	+1.37%		+1.51%	-3.27%

05-28	BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System Manufacturing License	CI
05-10	BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BioGend Therapeutics Co., Ltd.(TPEX:6733) added to S&P Global BMI Index

September 18, 2023 at 05:00 am

Latest news about BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System Manufacturing License	05-28	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-02	CI
BioGend Therapeutics Co., Ltd. Receives Notification from the Thai FDA That Revocart to Obtains A Thai Medical Device License	02-06	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
BioGend Therapeutics Co., Ltd.(TPEX:6733) added to S&P Global BMI Index	18/09/23	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/05/23	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	24/03/22	CI
BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	10/11/21	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	09/08/21	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	09/05/21	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	15/03/21	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	09/11/20	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	12/08/20	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	28/04/20	CI
Biogend Therapeutics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	06/08/19	CI
BioGend Therapeutics Completes Enrollment for The Pivotal Clinical Trial of One-Step Autologous Knee Cartilage Repair/Regeneration	26/06/18	CI
BioGend Therapeutics Co., LTD acquired Exactech Taiwan, Ltd.	30/12/17	CI

Chart BioGend Therapeutics Co., Ltd.

Duration

Period

More charts

BIOGEND THERAPEUTICS CO., LTD. is a medical equipment company mainly engaged in the development of biological aggregate. The Company is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The Company's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

37 TWD

Average target price

48 TWD

Spread / Average Target

+29.73%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOGEND THERAPEUTICS CO., LTD.	-3.27%	140M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research